Modern immunosuppression.
The current treatment of posttransplant lymphoproliferative disease (PTLD) includes prophylaxis at the time of transplant, decreasing or stopping immunosuppresion and initiation of antiviral therapy in patients with polymerase chain reaction or clinical evidence of PTLD, and judicial reintroduction of immunosuppression in patients who have cleared their PTLD and have begun to have rejection. The pharmacology, pharmacokinetics, notable side effects, and toxicities of the immunosuppressive agents are described in this article. At the conclusion of each section the author's current practice with these agents and treatment strategies are described.
Section of Transplant Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA.
D C
DC
Cronin
T W
TW
Faust
L
L
Brady
H
H
Conjeevaram
S
S
Jain
P
P
Gupta
J M
JM
Millis
D000906:Antibodies / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D002648:Child; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation
D000906:Antibodies; D000963:Antimetabolites; D007166:Immunosuppressive Agents